Catalyst Dossier · compiled by CeliA 🧫

Intellia Therapeutics, Inc. (NTLA)

In Vitro & In Vivo Diagnostic Substances · market cap $2.2B · as of 2026-07-01

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-06

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Intellia Therapeutics (NTLA) is a clinical-stage CRISPR gene-editing company with a ~$2.4B market cap and three Phase 3 programs: NTLA-2002 (hereditary angioedema), NTLA-2001 (ATTR cardiomyopathy), and nexiguran ziclumeran (neuromuscular disease). The company is in an acute financial crisis, reporting only $15.4M cash and an estimated runway of roughly two weeks, making near-term dilutive financing an effective certainty. Key binary catalysts are expected in H1 2027.

The catalyst path

2026-08-06Earningsimp 5/10
2027-01-01Regulatoryimp 6/10
2027-06-30Phase 3imp 8/10

Pipeline

Asset	Phase	Indication
NTLA-2002	Phase 3	Hereditary Angioedema
NTLA-2001	Phase 3	Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
Biological NTLA-2002	Phase 2	Hereditary Angioedema
nexiguran ziclumeran	Phase 3	Neuromuscular Disease

Price & technical context

3-month

+32.3%

6-month

+93.8%

12-month

+77.7%

52-wk range

$8.04–$27.98

vs 50-day MA

+24.6%

vs 200-day MA

+28.4%

Realized vol

103.3%

Max drawdown

-77.0%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for NTLA (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.